
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **IL6 (Interleukin 6):** A cytokine involved in inflammation and the maturation of B cells. It plays a role in immune response and is often associated with inflammatory processes.<br>- **CSF3 (Colony Stimulating Factor 3):** Also known as G-CSF, it is involved in the production, differentiation, and function of granulocytes.<br>- **ANGPT2 (Angiopoietin 2):** Involved in angiogenesis and endothelial cell function.<br>- **SERPINE1 (PAI-1):** A serine protease inhibitor that plays a role in fibrinolysis and is involved in the regulation of extracellular matrix degradation.<br>- **HMOX1 (Heme Oxygenase 1):** An enzyme that provides protection against oxidative stress.<br>- **CXCL8 (IL-8):** A chemokine involved in the recruitment of neutrophils to sites of inflammation.<br>- **CCL2 (MCP-1):** A chemokine that recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury and infection.<br>- **S1PR1 (Sphingosine-1-phosphate receptor 1):** Involved in the regulation of endothelial cell function and vascular maturation.<br>- **ICAM1 (Intercellular Adhesion Molecule 1):** Plays a role in stabilizing cell-cell interactions and facilitating leukocyte endothelial transmigration.<br><br>### Step 2: List the Key Cell Type Markers<br>- **SELE (E-selectin):** Expressed on endothelial cells activated by cytokines, involved in the adhesion of leukocytes to the endothelium.<br>- **CD93:** A marker associated with endothelial cells and involved in cell adhesion and phagocytosis.<br>- **PLVAP (Plasmalemma Vesicle Associated Protein):** An endothelial cell-specific protein involved in the formation of diaphragms in fenestrae, transendothelial channels, and caveolae.<br>- **FABP4 (Fatty Acid Binding Protein 4):** Expressed in adipocytes and macrophages, involved in fatty acid uptake and transport.<br>- **SPARCL1 (SPARC-like 1):** Associated with endothelial cells and involved in cell adhesion and migration.<br>- **TM4SF1 (Transmembrane 4 L Six Family Member 1):** Expressed in endothelial cells and involved in cell proliferation and migration.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and PanglaoDB, we can cross-reference these markers to identify their association with specific cell types. The presence of markers like SELE, CD93, PLVAP, and TM4SF1 strongly suggests an endothelial cell identity.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of markers such as SELE, CD93, PLVAP, and TM4SF1, the most probable general cell type for this cluster is **endothelial cells**. These markers are characteristic of cells involved in forming the lining of blood vessels and are often upregulated in tumor-associated vasculature.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Tumor-associated endothelial cells:** These cells are often found in the tumor microenvironment and are characterized by the expression of angiogenesis-related markers such as ANGPT2 and SERPINE1.<br>2. **Inflammatory endothelial cells:** Characterized by the expression of inflammatory cytokines and chemokines such as IL6, CXCL8, and CCL2, indicating a role in immune cell recruitment.<br>3. **Lymphatic endothelial cells:** Although less likely given the marker list, they can express some overlapping markers with blood endothelial cells, such as S1PR1.<br><br>The most likely subtype based on the markers is **tumor-associated endothelial cells**, given the context of breast cancer tissue and the expression of angiogenesis and inflammation-related markers.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of endothelial cells. The expression of markers such as SELE, CD93, PLVAP, and TM4SF1 supports this annotation. Within the endothelial cell category, the most probable subtype is tumor-associated endothelial cells, characterized by markers involved in angiogenesis and inflammation, which are commonly upregulated in the tumor microenvironment.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation of the cell cluster as "endothelial cells," specifically "tumor-associated endothelial cells," is consistent with the provided marker list and the context of breast cancer tissue. Here's the breakdown of the validation:<br><br>1. **Marker Consistency:**<br>   - The key markers used in the annotation, such as SELE, CD93, PLVAP, and TM4SF1, are present in the provided marker list and are well-known markers for endothelial cells.<br>   - Additional markers like ANGPT2 and SERPINE1 support the identification of tumor-associated endothelial cells, as they are involved in angiogenesis and are commonly upregulated in tumor environments.<br>   - Inflammatory markers such as IL6, CXCL8, and CCL2 further support the presence of endothelial cells involved in immune response and inflammation, which is typical in tumor-associated vasculature.<br><br>2. **Mixed Cell Type Consideration:**<br>   - While there are markers like FABP4, which can be associated with macrophages, the overall marker profile strongly supports an endothelial cell identity. The presence of inflammatory and angiogenesis-related markers aligns with the characteristics of tumor-associated endothelial cells.<br>   - There is no strong evidence of multiple distinct cell types that would necessitate flagging for mixed cell type consideration.<br><br>The annotation is well-supported by the marker list and the context of the dataset, leading to a valid conclusion of tumor-associated endothelial cells in the breast cancer tissue.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">endothelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>tumor-associated endothelial cells</li><li>inflammatory endothelial cells</li><li>lymphatic endothelial cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell dataset derived from human breast cancer tissue are generally well-executed, with a few areas that could be improved. <br><br>1. **Correctness of Annotations**: The final annotation identifies the main cell type as "endothelial cells," with a specific focus on "tumor-associated endothelial cells." This is a scientifically accurate conclusion given the context of breast cancer tissue and the presence of markers such as SELE, CD93, PLVAP, and TM4SF1, which are well-known endothelial markers. The inclusion of angiogenesis-related markers like ANGPT2 and SERPINE1 further supports the identification of tumor-associated endothelial cells, which are common in the tumor microenvironment.<br><br>2. **Balanced Consideration of Multiple Markers**: The annotation process demonstrates a balanced consideration of multiple markers. The analysis does not overly focus on a single marker but instead considers a range of markers that are relevant to endothelial cells and their subtypes. The inclusion of inflammatory markers such as IL6, CXCL8, and CCL2 adds depth to the analysis, suggesting the presence of inflammatory endothelial cells, which is plausible in a tumor context.<br><br>3. **Ability to Capture the General Picture**: The annotation captures the general picture of the cell populations present in the dataset. It identifies the main cell type and provides a plausible explanation for the presence of subtypes, such as tumor-associated and inflammatory endothelial cells. The analysis also considers the possibility of lymphatic endothelial cells, although it deems them less likely, which shows a comprehensive approach.<br><br>4. **Consideration of Marker Rank**: While the annotation process is thorough, it could have placed more emphasis on the rank of the markers. For instance, PCAT19, which appears first, is not discussed in the analysis. Although it may not be as well-characterized as other markers, its position suggests it could be significant and warrants at least a mention or investigation.<br><br>5. **Potential Oversights**: There is a minor oversight in not addressing the presence of FABP4, which is associated with macrophages and adipocytes. While the overall marker profile supports an endothelial identity, acknowledging the presence of such markers could provide a more nuanced view of potential mixed cell types or interactions within the tumor microenvironment.<br><br>Overall, the annotation is scientifically sound and provides a comprehensive view of the cell types present, with a few areas for improvement in marker rank consideration and potential mixed cell type acknowledgment.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    